TATAA-DEVELOPED TECHNOLOGIES

TATAA technologies and innovations

TATAA researchers support our customers with assay design, technologies, products, and unique solutions that enable processes that reduce costs and enhance reliability in bringing their products and treatments to the clinics.

PK/PD​ bioanalysis
HISTORY OF INNOVATION

TATAA Biocenter has a history of innovations

Researchers behind TATAA were among the pioneers developing quantitative real-time PCR and later single-cell, multiway, intracellular, and multimodal profiling. 

The DeltaAmp assay design to assess degradation, exogeneous spike-in controls to assess inhibition, ValidPrime and Alu-assays to assess contamination, interplate calibrators to eliminate inter-run variation, and reference gene panels are among the tools developed to ascertain highest possible quality of the measured data.

TATAA is also member of the CANCER-ID and SPIDIA consortia who contributed to numerous ISO and CEN guidelines. 

TATAA has a history of providing assay developement, design and optimization.

aav gene therapy

Two-tailed PCR

Short nucleic acids such as microRNAs are way too short to be targeted by two conventional primers required for PCR. Current methods therefore extend short nucleic acid targets by some means prior to amplification. This, however, compromises the sensitivity and the specificity of the assay. TATAA has found a solution. 

In Two-Tailed PCR, a single molecule, designed with a hair-pin structure, hybridizes with both its termini, referred to as hemiprobes, to the target. Each hemiprobe alone is too short to bind but being part of the same molecule binding is cooperative and their combined affinity is sufficient. This leads to greater sensitivity but also superior specificity as sequence variation has much greater impact in the short hemiprobe binding region.

Play Video

Direct Blood Genotyping (DBG)

Genetic testing is typically performed on venous blood samples collected at the Doctor’s office and sent to a central laboratory that extracts and analyses the DNA. Results are sent to the Doctor, who prescribes drugs and treatment to their patient based on the results. TATAA’s Direct Blood Genotyping (“DBG”) allows genetic testing to be performed at the Point of Care at the Doctor’s office with no extraction needed. Furthermore, capillary blood is sufficient, making the entire process simple and convenient.

×

Olink

"*" indicates required fields

What platform of interest?*
Name*

General Enquiries

Please fill in the form below and we’ll get back to you ASAP.

"*" indicates required fields

Name*

Courses

Please fill in the form for any courses request

"*" indicates required fields

Name*

Sign up to our Newsletter

"*" indicates required fields

Name*

Bioanalytical Services

Please fill in the form below and one of our bioanalytical experts will get back to you ASAP.

"*" indicates required fields

What services are you interested in?*
Hidden

Products

Please fill in the form below for any products request

"*" indicates required fields